جستجوی استاد راهنمای دانشگاهی

Dr. Susan Hua is an Associate Professor at the University of Newcastle's School of Biomedical Sciences and Pharmacy, specializing in translational nanopharmaceutics and therapeutic targeting. She established the first translational nanopharmaceutics laboratory in the Hunter region, focusing on drug delivery systems for gastrointestinal, musculoskeletal, and reproductive pathologies. Education: Bachelor of Pharmacy with Honours, University of Queensland (UQ) PhD in Neuroscience and Nanotechnology, UQ Research Interests: Her work centers on using nanotechnology to create targeted drug delivery systems for diseases such as chronic pain, inflammatory conditions, and obstetric complications. Key focuses include oxytocin receptor-targeted liposomes for uterine therapies and localized drug delivery to bypass biological barriers. Awards & Recognition: 2020 DVC(A) Educator Innovation Award 2017 NSW Premier's Early Career Researcher of the Year 2015 HMRI Early Career Researcher of the Year Grants & Collaborations: A/Prof Hua has secured over $5.5M in grants, including NHMRC and ARC funding. She collaborates with institutions like HMRI, John Hunter Hospital, and global teams on projects like nanoparticle-based treatments for preterm labor and uterine hemorrhage. Teaching & Leadership: She coordinates pharmacy programs, emphasizing clinical application and innovation. Her courses include Pharmacotherapeutics and Pharmacy Practice, with awards for teaching excellence (2020, 2011). Labs & Programs: Head of Therapeutic Targeting Program, University of Newcastle Director, Translational Pharmaceutics & Medical Technologies Theme (HMRI)

• Nanomedicine
• Therapeutic Targeting
• Drug Delivery Systems
• +۴ مورد دیگر

Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +۱۲ مورد دیگر

Sunitha Nagrath is a Professor of Chemical Engineering at the University of Michigan, leading the Nagrath Lab. Her research focuses on developing microfluidic and nanotechnology-based tools to isolate and analyze circulating tumor cells (CTCs) and extracellular vesicles (EVs) for cancer diagnostics and personalized medicine. She holds an AIMBE Fellowship and has pioneered technologies like the Graphene Oxide Chip and Microfluidic Labyrinth. Education PhD in Mechanical Engineering, Rensselaer Polytechnic Institute (2004) MS in Nuclear Engineering, Rensselaer Polytechnic Institute (2000) B.Tech in Chemical Engineering, Sri Venkateswara University (1992) Research Interests Her lab integrates engineering, biology, and clinical expertise to study CTCs' role in metastasis, develop high-throughput isolation methods, and leverage exosomes as liquid biopsy biomarkers. Key projects include: CTC-based monitoring of therapy response in lung and pancreatic cancers Microfluidic devices for simultaneous CTC and exosome analysis Functional studies of CTC-derived organoids for drug sensitivity testing Notable Achievements AIMBE Fellow (Junior Faculty, Harvard Medical School/MGH, 2008-2010) Over 150 peer-reviewed publications and patents on CTC/exosome technologies Recipient of the 2021-22 Chemical Engineering Staff Incentive Award (via lab member Mina Zeinali) Labs & Collaborations The Nagrath Lab collaborates with clinicians and engineers to translate technologies like the OncoBean Chip and EVOD chip into clinical settings. Current work emphasizes real-time CTC monitoring and exosome-based immuno-oncology strategies.

• Bio-MEMS and Microfluidics
• Nanotechnology
• Circulating Tumor Cells
• +۳ مورد دیگر

Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.

• Stem Cell Biology
• Genetic Engineering
• Epigenetics
• +۵ مورد دیگر

Dr. Thomas A. Hughes is an Associate Professor of Cancer Biology at the University of Leeds and Professor of Biosciences at York St John University. As a Group Leader at the Leeds Institute of Medical Research, he focuses on gene regulation, tumour microenvironment, and nanomedicine approaches to improve cancer outcomes. Specializes in breast cancer, colorectal cancer, and rare diseases Develops therapeutic strategies using microRNAs and biomarkers Collaborates with clinicians, engineers, and chemists for translational research His research integrates molecular pathology with clinical data through partnerships with Leeds NHS Trusts, aiming to identify novel biomarkers and targets for therapy. Recent work emphasizes cholesterol metabolism, oxysterol signaling, and nanomedicine-based drug delivery systems. Key contributions include: Over 80 peer-reviewed publications in cancer biology and molecular therapeutics Leadership in MSc programs in Molecular Medicine and Cancer Biology and Therapy Extensive experience in grant review, editorial work, and doctoral supervision Scientific awards include Fellowship of the Higher Education Academy. His lab has mentored 26 doctoral students and numerous alumni in academia, clinical practice, and industry.

• Cancer Biology
• Gene Regulation
• Breast Cancer
• +۶ مورد دیگر

Pedro A Hermida de Viveiros, MD serves as an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Northwestern University's Feinberg School of Medicine. His clinical practice focuses on solid tumor oncology with specialized expertise in sarcomas and precision medicine approaches. His research interests center on clinical development of novel therapeutic strategies for sarcomas and gastrointestinal stromal tumors (GIST), emphasizing biomarker-driven treatments and molecularly targeted therapies. Key areas include IDH1-mutant chondrosarcoma management, neoadjuvant response assessment in sarcomas, and immunotherapy-radiotherapy combinations for metastatic disease. Analysis of his recent publications reveals a consistent focus on translating molecular targets into clinical applications, particularly through phase 1-3 trials of targeted agents like ivosidenib and IDRX-42. His work bridges radiological assessment, pathological response, and precision oncology frameworks for rare solid tumors. Professional engagements include active membership in major oncology societies: American Society of Clinical Oncology (ASCO) Connective Tissue Oncology Society (CTOS) Sociedade Brasileira de Oncologia Clínica (SBOC) European Society for Medical Oncology (ESMO) He currently leads four active clinical trials through the Robert H. Lurie Comprehensive Cancer Center, including the CHONQUER phase 3 study of ivosidenib for IDH1-mutant chondrosarcoma and first-in-human trials of novel agents for advanced solid tumors and GIST. His work integrates translational research with clinical trial design to advance personalized treatment paradigms.

• Oncology
• Sarcoma Research
• Precision Medicine
• +۳ مورد دیگر

Dr. Jason Webber is a Senior Lecturer in Biomedical Sciences at Swansea University Medical School. He holds an honorary position as a Research Fellow at Cardiff University and is a board member of the UK Society for Extracellular Vesicles. His research focuses on extracellular vesicles (EVs), particularly their role in cancer progression and as biomarkers for aggressive tumors like prostate cancer. He completed his PhD at Cardiff University's Institute of Nephrology in 2009 and received a Prostate Cancer UK Career Development Fellowship (2014–2020). Dr. Webber's expertise includes EV biology, tumor microenvironment dynamics, and translational research. He actively contributes to teaching modules such as 'Genetics of Cancer' and 'Advanced Research Topics in Biomedical Science'. His work spans collaborations with institutions like Erasmus MC and the CIC bioGUNE in Spain. Key grants include funding for projects like 'Extracellular Vesicle Glycoproteins for Prostate Cancer Diagnosis (EVGlyProD)' and investigations into EV roles in bone metastasis and rare diseases like tuberous sclerosis complex. His research highlights EVs' dual role as functional mediators of tumor growth and potential biomarkers. Notable achievements include demonstrating EV-HSPG's role in stromal activation and developing methodologies for EV-based diagnostics. Dr. Webber supervises multiple PhD and MSc students, emphasizing mentorship in EV research and cancer biology.

• Extracellular Vesicles (EVs)
• Tumour Microenvironment
• Prostate Cancer
• +۶ مورد دیگر

João F. Mano is a Full Professor at the Department of Chemistry, University of Aveiro, and Director of the Doctoral Program on Biotechnology. He leads the COMPASS Research Group and serves as Vice-Director at CICECO - Aveiro Institute of Materials. His academic appointments include Invited Professor at University of Lorraine (France), Visiting Professor at KAIST (South Korea), and Adjunct Professor at Ajou University (South Korea). Education: PhD in Chemistry (1996, Technical University of Lisbon); D.Sc. in Tissue Engineering, Regenerative Medicine and Stem Cells (2012, University of Minho) Research Interests focus on Biomaterials for Regenerative Medicine , integrating Nanotechnology , Microtechnology , and Biofabrication . His group develops Bioinspired Materials using polymer chemistry, Decellularized Extracellular Matrix , and 3D Bioprinting to engineer Cell Microenvironments for therapeutic applications. Recent Publications highlight advancements in Human-Derived Hydrogels , Photopolymerizable Scaffolds , Magneto-Responsive Biomaterials , and Programmable Bioinks . Trends show emphasis on Organ-on-a-Chip integration, Smart Living Materials , and Green Bioprinting methodologies. Scientific Awards include: European Research Council Advanced Grants (2015, 2020) Fellow at IUPAC, European Academy of Sciences, and American Institute of Medical and Biological Engineering ERC Proof of Concept Grants Doctor Honoris Causa from University of Lorraine and Utrecht UNESCO Chair on Biomaterials George Winter Award (European Society for Biomaterials) Supervisions & Collaborations encompass 74+ MSc, 26+ PhD students, and 40+ postdocs. He co-founded METATISSUE and CELLULARIS Biomodels , and serves as Editor-in-Chief of Materials Today Bio .

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +۵ مورد دیگر

Sean J. Morrison is the founding Director of the Children’s Medical Center Research Institute at UT Southwestern (CRI) and a Howard Hughes Medical Institute Investigator. He holds the Mary McDermott Cook Chair in Pediatric Genetics and the Kathryne and Gene Bishop Distinguished Chair in Pediatric Research. Dr. Morrison earned his B.Sc. in Biology and Chemistry from Dalhousie University (1991), a Ph.D. in Immunology from Stanford University (1996), and completed a postdoctoral fellowship in Neurobiology at Caltech (1999). Education: B.Sc. - Dalhousie University (Biology & Chemistry, 1991) Ph.D. - Stanford University (Immunology, 1996) Postdoctoral Fellowship - Caltech (Neurobiology, 1999) Research Interests: Dr. Morrison’s laboratory investigates the mechanisms that maintain adult tissues and how cancer cells exploit these processes to form tumors. His team compares stem cell and cancer cell replication mechanisms to develop novel regenerative medicine and anticancer therapies. Key areas include: Stem cell self-renewal and aging Metabolic regulation of hematopoietic stem cells Leptin Receptor+ stromal cell function Cancer progression and metastasis Proteostasis and niche biology Mechanotransduction in stem cell niches Publications reveal trends in stem cell metabolism, tumor heterogeneity, and niche dynamics across Science , Nature , and Cell . His work on retrotransposons in stem cell activation (2024) and β-adrenergic receptor inhibition in hematopoietic regeneration (2024) highlights emerging therapeutic targets. Awards & Recognitions: Dr. Morrison is an elected member of the U.S. National Academy of Medicine (2018), National Academy of Sciences (2020), and EMBO (2023). He received the Presidential Early Career Award (2003), MERIT Award from NIA (2009), and UT Southwestern’s Excellence in Postdoctoral Mentoring Award (2020). Mentorship & Leadership: Dozens of graduate students and postdoctoral fellows from his lab have secured academic leadership roles or industry positions. He served as President of the International Society for Stem Cell Research (2015–2016) and actively engages in public policy debates about stem cell research, including Michigan’s constitutional protections for regenerative medicine.

• Stem Cell Biology
• Cancer Progression
• Metabolism
• +۳ مورد دیگر

Hee Kwon Song, Ph.D. is an Associate Professor of Radiology at the University of Pennsylvania , affiliated with the Institute for Translational Medicine and Therapeutics and the Penn Center for Musculoskeletal Disorders . His expertise lies in MRI physics and MRI engineering , focusing on novel dynamic imaging strategies. Education: BS in Electrical Engineering, Northwestern University (1991) MS in Bioengineering, University of Pennsylvania (1994) PhD in Bioengineering, University of Pennsylvania (1999) Master of Law, University of Pennsylvania Carey Law School (2021) Dr. Song’s research specializes in dynamic contrast-enhanced MRI (DCE-MRI) using radial data acquisition and KWIC reconstruction for ultra-fast imaging. His work enables retrospective respiratory motion compensation and flexible resolution adjustments in tumor treatment monitoring ( lung, liver, breast, kidney, ovarian ). Applications extend to non-contrast MRA and tissue T1 mapping . Selected Publications demonstrate his focus on accelerated MRI , bone-selective imaging , and deep learning reconstruction , with collaborations spanning Medicine, Obstetrics and Gynecology, Neurology , and Radiation Oncology . Contact: heekwon.song@pennmedicine.upenn.edu

• MRI Physics
• Biomedical Engineering
• Medical Imaging
• +۲ مورد دیگر

Xin Lu is the John M. and Mary Jo Boler Collegiate Associate Professor in the Department of Biological Sciences at the University of Notre Dame. She is a full member of the Harper Cancer Research Institute (HCRI), the Boler-Parseghian Center for Rare and Neglected Diseases (CRND), and the Tumor Microenvironment and Metastasis Program at the Indiana University Simon Comprehensive Cancer Center. Her research spans tumor immunology, immunotherapy, metastasis, and multi-omics, with a focus on prostate, breast, and rare cancers. Ph.D. in Molecular Biology, Princeton University (2004–2010) B.S. in Biological Sciences, Tsinghua University, China (2000–2004) Postdoctoral Fellow, Dana-Farber Cancer Institute and M.D. Anderson Cancer Center (2010–2016) Assistant to Associate Professor, University of Notre Dame (2017–Present) Dr. Lu's research investigates the molecular and cellular mechanisms of tumor-immune crosstalk, particularly the role of myeloid-derived suppressor cells (MDSCs) and neutrophils in promoting immunotherapy resistance. Her lab uses genetically engineered mouse models, functional genomics, single-cell and spatial transcriptomics, and high-throughput screening to uncover novel therapeutic targets. A major focus is on how cancer-cell-intrinsic oncogenic signaling shapes the immunosuppressive tumor microenvironment. Her recent publications reveal mechanisms such as Acod1-mediated ferroptosis resistance in neutrophils, Pygo2-driven immunosuppression in prostate cancer, and the efficacy of ketogenic diets in overcoming checkpoint blockade resistance. These studies span multiple disciplines including cancer biology, immunology, metabolism, epigenetics, and bioengineering, reflecting a highly integrative approach to immuno-oncology. Jane Coffin Childs Postdoctoral Fellow John M. and Mary Jo Boler Faculty Appointment Cluster Chair, Cellular & Molecular Biology, IBMS PhD Program Junior Chair, Boler-Parseghian Center for Rare and Neglected Diseases Dr. Lu mentors a diverse team of graduate students, postdoctoral fellows, and undergraduates. Her lab is actively recruiting and has secured funding from federal agencies and private foundations. She collaborates with chemists, bioengineers, and bioinformaticians to develop novel therapeutics, including antibody-drug conjugates, CAR-NK cells, and small-molecule inhibitors. Her lab also develops innovative platforms like mini-tumor chips for immunotherapy evaluation. Her lab maintains affiliations with multiple interdisciplinary centers including the Warren Family Center for Drug Discovery, Eck Institute for Global Health, and Berthiaume Institute for Precision Health, underscoring her collaborative and translational research vision.

• Cancer Biology
• Tumor Microenvironment
• Tumor Immunology and Immunotherapy
• +۱۲ مورد دیگر

Professor Kim Midwood serves as Professor of Matrix Biology and Kennedy Director of Graduate Studies at the University of Oxford's Kennedy Institute of Rheumatology, leading research on extracellular matrix dynamics in inflammatory diseases and cancer. Her academic foundation includes: BSc (Hons) in Biochemistry from the University of Edinburgh (1995) PhD in Pathology from the University of Edinburgh (1999), investigating extracellular matrix changes in arthritis Her research centers on matrix immunology, particularly tenascin-C's role in rheumatoid arthritis, tumor microenvironments, and fibrosis. She examines how tissue-specific matrix composition dictates immune cell behavior through toll-like receptor signaling and chemokine networks, revealing novel therapeutic targets for chronic inflammatory conditions. Publications from 2013-2025 demonstrate evolving focus from arthritis mechanisms to broader applications in cancer immunotherapy and regenerative medicine, consistently highlighting matrix molecules as central regulators of disease progression. Her accolades include: MRC New Investigators Award (2007) Arthritis Research UK Senior Fellowship (2012) She directs the Matrix Immunology research group (established 2004 at Imperial College London, relocated to Oxford in 2011) and founded biotech company Nascient Ltd (2012) to translate matrix-targeting discoveries into clinical therapies.

• Matrix Biology
• Immunology
• Rheumatology
• +۵ مورد دیگر

Naim U. Rashid, PhD, is an Associate Professor with tenure in the Department of Biostatistics at the UNC Gillings School of Global Public Health and holds a joint appointment as Research Associate Professor at the Lineberger Comprehensive Cancer Center. He serves as Associate Director of the Lineberger Biostatistics Shared Resource and co-directs the Biostatistics Cores of the UNC Pancreatic and Breast Cancer SPOREs. His work bridges statistical methodology development with collaborative cancer research, focusing on translating genomic discoveries into clinical applications. Dr. Rashid's research spans precision medicine, genomics, statistical computing, and machine learning with specific applications to pancreatic and breast cancers. His lab develops novel statistical methods for high-throughput genomic data analysis, cancer subtyping, missing data problems in deep learning, and clinical trial design. Recent work includes developing an AI tool that recommends optimal clinical trials to pancreatic cancer patients, funded by a $311,000 Department of Defense grant in 2024. His methodological contributions focus on improving replicability in gene signature selection and clinical prediction, with emphasis on addressing racial disparities in cancer outcomes. His publication record shows consistent output in top statistical and medical journals, with recent work focusing on high-dimensional statistics, missing data methods, and cancer genomics. His research demonstrates a clear trajectory from methodological innovation to clinical implementation, particularly in pancreatic cancer where his PurIST classifier has gained recognition. The work increasingly incorporates machine learning approaches while maintaining strong statistical foundations. Delta Omega Faculty Award (2021, UNC Chapel Hill) IBM and R.J. Reynolds Junior Faculty Development Award (2017, UNC Chapel Hill) Barry H. Margolin Dissertation Award (2013, UNC Chapel Hill) Training Grant recipient (2006-2011, Genomics and Cancer) Dr. Rashid actively mentors graduate students and serves as trial statistician on multiple cancer clinical trials. He teaches BIOS 735, a doctoral-level course on statistical computing, and is involved with the Translational Breast Cancer Research Consortium Statistical Working Group. His lab collaborates extensively with clinicians at UNC Lineberger and beyond, with recent work including the PROCLAIM Study examining mHealth apps to improve diverse recruitment in pancreatic cancer trials. The Rashid Lab focuses on developing computational tools that directly impact clinical decision-making while addressing methodological challenges in genomic data analysis.

• Precision medicine
• Genomics
• Statistical computing
• +۷ مورد دیگر

Nadya Dimitrova is an Assistant Professor in the Department of Molecular, Cellular, and Developmental Biology at Yale University, affiliated with the Yale School of Medicine. She holds secondary appointments in Genetics and is a member of multiple interdisciplinary centers, including the Center for RNA Science and Medicine. Her research focuses on long non-coding RNAs (lncRNAs) and their roles in cancer biology, particularly in tumor suppression and oncogenesis. Dimitrova earned her Sc.B. in Biochemistry from Brown University (2002), a Ph.D. from The Rockefeller University (2009), and completed postdoctoral training at MIT's Koch Institute. Notable awards include the HHMI Predoctoral Fellowship, Damon Runyon Postdoctoral Fellowship, and the 2023 Yale Cancer Center Class of '61 Award. Her lab explores lncRNA mechanisms using genomic and genetic tools, aiming to uncover their roles in cancer pathways. Recent work highlights lncRNAs' roles in metastasis, cardiac hypertrophy, and p53 signaling. Collaborations with researchers like Antariksh Tyagi and Clara Liao drive translational insights into RNA-based therapies. Education: Sc.B., Brown University (2002); Ph.D., The Rockefeller University (2009). Research interests include lncRNA regulation, cancer transcriptomics, and RNA-driven disease mechanisms. Her lab integrates systems biology approaches to dissect lncRNA functions in health and disease.

• Long Non-Coding RNAs
• Cancer Biology
• Molecular Biology
• +۳ مورد دیگر

Dr. Albert Koulman is a Principal Research Associate at the University of Cambridge, affiliated with the Metabolic Research Laboratories (MRL) within the Institute of Metabolic Science. His work focuses on developing advanced analytical methods for metabolomics and lipidomics to understand metabolic processes in diseases. Department: Department of Clinical Biochemistry, University of Cambridge Key Roles: Scientific Director of the NIHR BRC Metabolomics and Lipidomics facility Research Interests 1. Metabolism in Pregnancy & Early Life: Collaborates with international teams to study lipid metabolism during pregnancy and infancy, developing biomarkers for gestational diabetes, infant nutrition, and childhood obesity risks. 2. Technological Innovations: Leads development of single-cell lipidomics and organelle-specific lipid profiling, establishing a full pipeline from sample preparation to bioinformatics. 3. Nutritional Biomarker Methodology: Specializes in dried blood spot applications for lipid analysis in clinical and population studies, supported by the MRC Epidemiology Unit. Article Trends Recent publications highlight his expertise in lipid metabolism across diseases (e.g., diabetes, melanoma, NAFLD). Key themes include sexual dimorphism in lipid biosynthesis, vitamin D dynamics during exercise, stromal lipid influences on cancer progression, and malnutrition recovery protocols. Methodological advancements (LC-MS/MS, single-cell analysis) and global health applications (Gambian maternal nutrition, pediatric rehabilitation) are recurring topics. Group Members & Collaborations Dr. Ben Jenkins (Analytical Chemist) Ms. Paulina Guevara Dominguez (Research Assistant) Ms. Nina van der Velde (MPhil Student) Collaborators: Sue Ozanne (Pregnancy Metabolism), MJFF (Parkinson’s research), MRC (Epidemiology Unit) Research Funding Biotechnology and Biological Sciences Research Council (BBSRC) JPI (Joint Programming Initiative) Michael J. Fox Foundation (MJFF) Medical Research Council (MRC) National Institute for Health and Care Research (NIHR)

• Metabolomics
• Lipidomics
• Analytical Chemistry
• +۴ مورد دیگر